Skip to main content
OM logo

OM · Outset Medical, Inc.

Track OM — free
$2.81 -0.10 (-3.44%) At close · Nov 20
Market Cap
$53.03M
Shares
18.87M
Volume · Nov 20 81.34K Avg daily vol (3M) 140.67K

Price & Indicators

 

Key stats

Close
$2.81
Fri 20 Nov
Open
$2.91
Fri 20 Nov
Average volume, 30 days
96K
shares a session
Short interest
813K
4.3% of shares · 8.6 days to cover
Day range
$2.77$3.02
Open $2.91 Close $2.81
52-week closing range
$2.81$5.68
Close $2.81 50.5% under the high
Short volume, last session
55%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 4
Price history
Sep 2020 to Nov 2026

Up next

Feb 10, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 4
Earnings call
Revenue grew 14% with 2026 guidance reiterated

Outset Medical reported third-quarter revenue of $33.6 million, up 14% year-over-year, and reiterated 2026 revenue guidance of $125 million to $130 million. Non-GAAP gross margin reached 40.8%.

4 source passages
Welcome to Outset Medical's third quarter 2026 earnings call. Revenue of $33.6 million was up 14% year-over-year and up 6% sequentially. Third quarter non-GAAP gross margin was 40.8%, up approximately 100 basis points compared to last year We are reiterating full-year revenue guidance of $125 million to $130 million. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows as gross margin expands

Outset Medical, Inc. reported quarterly revenue growth of 14% and nine-month revenue growth of 3%. Gross margin improved to 40.7% for the quarter and 41.9% for nine months, driven primarily by higher-margin service and other revenue.

Revenue $33.6M ▲ 14.2% Net loss $14.69M Diluted EPS -$0.78
Read from the MD&A section
4 source passages
As used in this Quarterly Report, references to the “Company,” “we,” “us,” “our,” or similar terms refer to Outset Medical, Inc. Total revenue | 33,596 | 29,431 | 4,165 | | 14% | 93,094 | 90,602 | 2,492 | | 3% Gross margin | 40.7% | 39.4% | | | | 41.9% | 38.1% | | | These improvements in gross profit and gross margin were primarily driven by higher gross margin on service and other revenue. Open the document at this passage
Nov 4
Current report 8-K
Revenue rises 14%, 2026 guidance reiterated

Outset Medical reported third-quarter revenue of $33.6 million, up 14%, gross margin of 40.7% and net loss of $14.7 million. It reiterated 2026 revenue guidance of $125 million to $130 million.

Financial results
5 source passages
Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the third quarter ended September 30, 2026. Net revenue totaled $33.6 million, an increase of 14% compared to the prior-year period and an increase of 6% sequentially. Gross margin expanded to 40.7%, an increase of 130 basis points compared to the prior-year period. Net loss was $14.7 million compared to net loss of $17.8 million in the third quarter of 2025. Outset reiterated its 2026 revenue guidance of $125 million to $130 million and continues to expect non-GAAP gross margin to be in the low-40% to mid-40% range for the full year. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$121.97M
Trailing 12 months
Net income (TTM)
−$71.14M
Trailing 12 months
Revenue growth YoY
+14.2%
Year over year
Operating margin
-51.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-80.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$72.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.9%
Year over year · more shares
Price change (1Y)
-36.7%
Trailing year
Short interest
4.3%
Latest settlement · 8.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Third-quarter revenue grew 14%, gross margin expanded 130 basis points, operating expenses fell 5%, and GAAP net loss narrowed; the HCA refresh agreement, estimated $150 million refresh opportunity, 96% customer retention, reiterated guidance, and potential HHS support provide commercial positives. Risks include a wider non-GAAP loss, lower product gross margin, significant cash use, potential gross-margin pressure from console mix, and uncertainty over implementation of the HHS plan.

Bullish
  • + Cumulative retention among parent customers that purchased Tablo consoles reached 96% since commercial launch. new
  • + The HHS Kidney Care National Plan was viewed as a potential policy tailwind that could encourage broader home-dialysis adoption and new-technology adoption. new
  • + Management reiterated full-year 2026 revenue guidance of $125 million to $130 million and low-40% to mid-40% non-GAAP gross-margin guidance. new
Bearish
  • − Non-GAAP net loss widened to $12.9 million from $12.4 million in the prior-year period. new
  • − Product gross margin declined 150 basis points year-over-year to 44.2%. new
  • − A higher mix of console sales could push full-year non-GAAP gross margin toward the lower end of the guidance range. new
  • − The ultimate impact of the HHS Kidney Care National Plan remains dependent on implementation. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −31%
below
Price vs 50-day avg −25%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −31%
trailing
6-month return −45%
trailing
YTD return −24%
this year
Relative strength −35%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-17% holders QoQ · +9 funds added
Insider flow Distributing
Net -$29.0K over 90 days · 100% sells
Short interest Falling
4.31% of shares out · ▼ -12.8% MoM · 8.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
77 holders — mid 3-yr range
Squeeze score 50
elevated · 0–100
Fundamentals
Fair
Revenue growth +5%
Y/Y
Gross margin 39%
expanding
EPS growth +85%
Y/Y
Free cash flow $-47.1M
Balance sheet $61.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −51%
past year
ATR 10.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 7
Latest guidance · from the Earnings Call filed Nov 4, 2026
Full-year revenue guidance · full-year 2026 Maintained $125M – $130M
Aug 6, 2026 $125M – $130M changed to Nov 4, 2026 $125M – $130M
prior FY $119.48M midpoint +6.7% Y/Y
Guided vs delivered · last 7 settled
2025 revenue 2025
guided $115M – $120M
$119.48M In line
2024 revenue 2024
guided $110M
$113.69M Beat +3.4%
2023 revenue guidance 2023
guided $130M
$130.38M Beat +0.3%
Revenue 2022
guided $111M – $113M
$115.38M Beat +3.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−31% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-17% holders QoQ · +9 funds added
Insider flow Distributing
Net -$29.0K over 90 days · 100% sells
Short interest Falling
4.31% of shares out · ▼ -12.8% MoM · 8.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
77 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 0% Range high $6
vs 200-day avg -31% vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Total cash, including restricted cash, cash equivalents and investment securities $140.7M As of September 30, 2026 —
Total cash, including restricted cash, cash equivalents and short-term investments $140.7M as of September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OM
Outset Medical, Inc.
this stock
$53.03M -24.3% +5.1% — 4.3%
ABT
Abbott Laboratories
$178.39B -17.8% +5.7% 38.4 1.1%
MDT
Medtronic plc
$127.84B +4.0% +8.4% 24.6 1.8%
SYK
Stryker Corp
$118.01B -11.8% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$60.85B -56.0% +12.5% 17.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
77
% held
64.8%
Net QoQ
-1.6M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
36
View
Short & Settlement
Short Interest Falling
Shares short
812.8K
Days to cover
8.6d
Change
-119.8K sh
View
Short Volume
Short vol %
55%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
62
Value
$269
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
49.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$29.0K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$119.5M
Net income (FY)
$-81.7M
EPS diluted
$-5.37
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
17

Outset Medical reported third-quarter revenue of $33.6 million, up 14%, gross margin of 40.7% and net loss of $14.7 million. It reiterated 2026 revenue guidance of $125 million to $130 million.

View
Proposed Sales
Value
$18.4K
Shares
4.4K
Filed
Nov 16, 2026
View
Exempt Offerings
Offering
$3.9M
Filed
Jan 21, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Outset Medical Reports Third Quar…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
OM -24.7% -31.5% -44.6% -30.3% -24.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -16.1% -22.2% -35.4% -21.6% -25.4%
Key facts CIK 1484612 CUSIP 690145206 13F (30d) 85 filings 70 filers Visit website Investor relations